$GFLT
GenFlat Holdings, Inc.

2023 Q3 Form 10-Q Financial Statement

#000165495423009220 Filed on July 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $1.884K
YoY Change -100.0% -70.6%
Cost Of Revenue $0.00 $1.884K
YoY Change -70.6%
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin 0.0%
Selling, General & Admin $19.83K $28.84K $65.41K
YoY Change -32.02% -55.91%
% of Gross Profit
Research & Development $0.00
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $19.83K $28.84K $65.41K
YoY Change -32.02% -55.91% -81.12%
Operating Profit -$19.83K -$28.84K -$63.53K
YoY Change -32.02% -54.6% -81.31%
Interest Expense $2.824K $2.427K $6.740K
YoY Change 180.72% -63.99% -86.52%
% of Operating Profit
Other Income/Expense, Net -$2.824K -$2.427K $10.57K
YoY Change -17.18% -122.96% -2475.28%
Pretax Income -$22.65K -$31.27K -$52.96K
YoY Change -30.48% -40.96%
Income Tax
% Of Pretax Income
Net Earnings -$22.65K -$31.27K -$52.96K
YoY Change -30.47% -40.96% -84.44%
Net Earnings / Revenue -2810.93%
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 21.30M shares 21.30M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.41K $22.07K $25.33K
YoY Change 109.56% -12.87%
Cash & Equivalents $27.41K $22.07K $25.33K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $0.00
Prepaid Expenses $477.0K
Receivables
Other Receivables
Total Short-Term Assets $120.7K $120.8K $156.7K
YoY Change -11.47% -22.93%
LONG-TERM ASSETS
Property, Plant & Equipment $2.214K
YoY Change
Goodwill
YoY Change
Intangibles $186.3K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $120.7K $120.8K $156.7K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $120.7K $120.8K $156.7K
YoY Change -11.47% -22.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $91.93K $92.22K $111.8K
YoY Change 20.5% -17.53%
Accrued Expenses $8.448K $5.659K $2.891K
YoY Change -28.16% 95.75%
Deferred Revenue
YoY Change
Short-Term Debt $111.1K $101.4K $250.0K
YoY Change 117.12% -59.42%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $211.5K $199.3K $364.7K
YoY Change 51.9% -45.35%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $211.5K $199.3K $364.7K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $211.5K $199.3K $364.7K
YoY Change 51.9% -45.35%
SHAREHOLDERS EQUITY
Retained Earnings -$3.520M -$3.498M -$3.353M
YoY Change 3.99% 4.32%
Common Stock $21.30K $21.30K $20.85K
YoY Change 0.0% 2.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$90.82K -$78.55K -$208.0K
YoY Change
Total Liabilities & Shareholders Equity $120.7K $120.8K $156.7K
YoY Change -11.47% -22.93%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$22.65K -$31.27K -$52.96K
YoY Change -30.47% -40.96% -84.44%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$110.00 -$290.00 -$33.86K
YoY Change -102.4% -99.14% 50.06%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $5.450K $8.170K $8.170K
YoY Change -33.29% 0.0%
Cash From Investing Activities $5.450K $8.171K $8.172K
YoY Change -33.29% -0.01% -104.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $0.00 $25.00K
YoY Change -100.0% -100.0% -89.15%
NET CHANGE
Cash From Operating Activities -110.0 -$290.00 -$33.86K
Cash From Investing Activities 5.450K $8.171K $8.172K
Cash From Financing Activities 0.000 $0.00 $25.00K
Net Change In Cash 5.340K $7.881K -$684.00
YoY Change -143.59% -1252.19% -108.7%
FREE CASH FLOW
Cash From Operating Activities -$110.00 -$290.00 -$33.86K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
106868 usd
CY2023Q2 us-gaap Revenues
Revenues
0 usd
CY2022Q2 us-gaap Revenues
Revenues
1884 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-58722 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
11440 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-31267 usd
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
14192 usd
CY2023Q1 us-gaap Advance Rent
AdvanceRent
7000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-63528 usd
CY2023Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
CY2023Q2 dei Entity Central Index Key
EntityCentralIndexKey
0001796949
CY2023Q2 dei Amendment Flag
AmendmentFlag
false
CY2023Q2 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--02-28
CY2023Q2 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q2 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21303000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21303000 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21303000 shares
CY2023Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
7000 usd
CY2023Q2 dei Document Type
DocumentType
10-Q
CY2023Q2 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q2 dei Document Period End Date
DocumentPeriodEndDate
2023-05-31
CY2023Q2 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q2 dei Entity File Number
EntityFileNumber
000-56214
CY2023Q2 dei Entity Registrant Name
EntityRegistrantName
Healthcare Business Resources Inc.
CY2023Q2 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q2 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3639946
CY2023Q2 dei Entity Address Address Line1
EntityAddressAddressLine1
718 Thompson Lane
CY2023Q2 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 108-273
CY2023Q2 dei Entity Address City Or Town
EntityAddressCityOrTown
Nashville
CY2023Q2 dei Entity Address State Or Province
EntityAddressStateOrProvince
TN
CY2023Q2 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
37204
CY2023Q2 dei City Area Code
CityAreaCode
615
CY2023Q2 dei Local Phone Number
LocalPhoneNumber
856-5542
CY2023Q2 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q2 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q2 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q2 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q2 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q2 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q2 dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21303000 shares
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
22073 usd
CY2023Q2 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
98697 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
120770 usd
CY2023Q2 us-gaap Assets
Assets
120770 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
92217 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5659 usd
CY2023Q2 us-gaap Advance Rent
AdvanceRent
7000 usd
CY2023Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
94443 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
199319 usd
CY2023Q2 us-gaap Liabilities
Liabilities
199319 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
21303 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3397695 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3497547 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-78549 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
120770 usd
CY2023Q2 hbr Revenue
Revenue
0 usd
CY2022Q2 hbr Revenue
Revenue
1884 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12691 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18058 usd
CY2023Q2 us-gaap Professional Fees
ProfessionalFees
16149 usd
CY2022Q2 us-gaap Professional Fees
ProfessionalFees
47354 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
28840 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
65412 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-28840 usd
CY2022Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
17310 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
2427 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
6740 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2427 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10570 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-31267 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-52958 usd
CY2023Q2 hbr Loss Per Share Basic
LossPerShareBasic
-0.00
CY2022Q2 hbr Loss Per Share Basic
LossPerShareBasic
-0.00
CY2023Q2 hbr Loss Per Share Diluted
LossPerShareDiluted
-0.00
CY2022Q2 hbr Loss Per Share Diluted
LossPerShareDiluted
-0.00
CY2023Q2 hbr Weighted Average Shares Outstanding Basic
WeightedAverageSharesOutstandingBasic
20853000 shares
CY2022Q2 hbr Weighted Average Shares Outstanding Basic
WeightedAverageSharesOutstandingBasic
20853000 shares
CY2023Q2 hbr Weighted Average Shares Outstanding Diluted
WeightedAverageSharesOutstandingDiluted
20853000 shares
CY2022Q2 hbr Weighted Average Shares Outstanding Diluted
WeightedAverageSharesOutstandingDiluted
20853000 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-78549 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-171369 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
16326 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-52958 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-208001 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-31267 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-52958 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
11440 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
16326 usd
CY2023Q2 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0 usd
CY2022Q2 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-17310 usd
CY2023Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
17246 usd
CY2022Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
35066 usd
CY2023Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2291 usd
CY2022Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-14980 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-290 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33856 usd
CY2023Q2 us-gaap Proceeds From Sale Of Notes Receivable
ProceedsFromSaleOfNotesReceivable
8171 usd
CY2022Q2 us-gaap Proceeds From Sale Of Notes Receivable
ProceedsFromSaleOfNotesReceivable
8172 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8171 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8172 usd
CY2023Q2 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
CY2022Q2 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
150000 usd
CY2023Q2 hbr Proceeds From Notes Payable Related Party
ProceedsFromNotesPayableRelatedParty
0 usd
CY2022Q2 hbr Proceeds From Notes Payable Related Party
ProceedsFromNotesPayableRelatedParty
225000 usd
CY2023Q2 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 usd
CY2022Q2 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
50000 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
7881 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-684 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14192 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26013 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22073 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25329 usd
CY2023Q2 us-gaap Interest Paid Net
InterestPaidNet
5135 usd
CY2022Q2 us-gaap Interest Paid Net
InterestPaidNet
5135 usd
CY2023Q2 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022Q2 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023Q2 us-gaap Securities Borrowed Credit Loss Expense Reversal
SecuritiesBorrowedCreditLossExpenseReversal
16172 usd
CY2022Q2 us-gaap Securities Borrowed Credit Loss Expense Reversal
SecuritiesBorrowedCreditLossExpenseReversal
0 usd
CY2023Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2023Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2023Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2023Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023Q2 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
7000 usd
CY2023Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
7000 usd

Files In Submission

Name View Source Status
0001654954-23-009220-index-headers.html Edgar Link pending
0001654954-23-009220-index.html Edgar Link pending
0001654954-23-009220.txt Edgar Link pending
0001654954-23-009220-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hbr-20230531.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
hbr-20230531_cal.xml Edgar Link unprocessable
hbr-20230531_def.xml Edgar Link unprocessable
hbr-20230531_lab.xml Edgar Link unprocessable
hbr-20230531_pre.xml Edgar Link unprocessable
hbr_10q.htm Edgar Link pending
hbr_ex311.htm Edgar Link pending
hbr_ex312.htm Edgar Link pending
hbr_ex321.htm Edgar Link pending
hbr_ex322.htm Edgar Link pending
hbr_ex42.htm Edgar Link pending
hbr_ex42img3.jpg Edgar Link pending
hbr_ex42img4.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
hbr_10q_htm.xml Edgar Link completed